BioNTech SE Revenue in 2025

BioNTech SE reported $3.2B in revenue for fiscal year 2025. This represents a growth of 5.7% compared to the 2024 figure of $3.0B.

A single company generated $20.7 billion in revenue during 2021 by developing the world's first approved mRNA-based medicine, then watched that revenue collapse to $3.0 billion just three years later as pandemic demand evaporated. BioNTech SE, the Mainz, Germany-based immunotherapy company co-founded by physicians Ugur Sahin and Ozlem Tureci in 2008, now faces the defining strategic inflection point of its 17-year existence: transforming from a one-product COVID-19 vaccine enterprise into a diversified oncology powerhouse before its $19.0 billion cash hoard depletes. Revenue declined 28% year-over-year from $4.2 billion to $3.0 billion, driven by collapsing demand for the Pfizer-partnered Comirnaty COVID-19 vaccine. The company swung from a net profit of $1014.0 million in 2023 to a net loss of $725.2 million in 2024, with diluted loss per share of $3 ($3.00). Research and development expenses surged 26% to $2.5 billion as BioNTech aggressively funded late-stage oncology trials. The operating loss of $1.8 billion represented the company's first significant annual deficit since its 2019 Nasdaq IPO. In November 2024, BioNTech paid $800 million upfront to acquire Biotheus, securing full global rights to BNT327 and adding a Chinese R&D hub with over 300 employees. The company has guided 2025 total revenues between $1.9 billion and $2.4 billion, implying further contraction. The cash position of $19.0 billion provides approximately 6-8 years of runway at current burn rates, but the clock is ticking. The stakes are measurable: the global oncology drug market exceeded $200 billion in 2024, with checkpoint inhibitors alone generating over $40 billion annually. The 2024 annual report explicitly states that BioNTech does not expect to report positive net income for the 2025 financial year, acknowledging the heavy investment phase ahead. The company built the development of the world's first approved mRNA-based medicine — the Pfizer-partnered Comirnaty COVID-19 vaccine — which generated peak revenues of $20.7 billion in 2021. For fiscal year 2024, BioNTech reported total revenues of $3.0 billion ($3.0 billion), a 28% decline from 2023, with 88% derived from COVID-19 vaccine sales. The company posted a net loss of $725.2 million ($3 per share) as R&D expenses surged 26% to $2.5 billion to fund an aggressive oncology pipeline shift. BioNTech employs approximately 7,807 people globally and maintains $19.0 billion in cash and securities. The company's strategic transformation centers on two priority oncology platforms: the bispecific antibody BNT327 (acquired through the $800 million Biotheus purchase in November 2024) targeting PD-L1 and VEGF-A, and mRNA cancer immunotherapies including individualized neoantigen vaccines. The company trades on Nasdaq under ticker BNTX with a market capitalization of approximately $22.7 billion. The dominant revenue stream remains the Pfizer collaboration on Comirnaty, the COVID-19 mRNA vaccine, which accounted for 73% of total 2024 revenues ($2.2 billion of $3.0 billion total). This collaboration generated $15.0 billion for BioNTech in 2022, $3.6 billion in 2023, and $2.2 billion in 2024, demonstrating the steep demand cliff as COVID-19 transitioned from pandemic to endemic status. The second revenue stream comprises pandemic preparedness contracts with governmental authorities, most notably the German Federal Ministry of Health, which contributed $764.1 million (25% of total 2024 revenues) through contracts for strategic vaccine reserves and variant-adapted vaccine development. Other customers contributed a mere $41.9 million (2% of revenues), underscoring the extreme revenue concentration risk. The gross margin on revenues was exceptionally high at 90.2% in 2024 ($2.2 billion gross profit on $2.4 billion BioNTech SE standalone revenues), though this is somewhat misleading because the cost of sales primarily reflects Pfizer's profit share rather than traditional manufacturing costs. On a consolidated group basis, cost of sales was $590.0 million against $3.0 billion in revenues, yielding a gross margin of 80.3%. In 2024, the company spent $2.5 billion on R&D — 82% of total revenues — making it one of the most R&D-intensive public biotechnology companies globally. This spending breaks down into $257.2 million for COVID-19 vaccine development (down 25% from 2023) and $2.2 billion for non-COVID programs (up 37%), with the oncology pipeline consuming the vast majority. SG&A expenses totaled $652.9 million in 2024, up 7% from 2023, driven by commercial IT platform investments and headcount growth. BioNTech's cash and cash equivalents plus security investments stood at $19.0 billion as of December 31, 2024, providing substantial but not infinite runway. At the 2024 burn rate of approximately $1.2 billion in net losses plus capital expenditures, this represents roughly 15 years of funding, though the company has signaled intentions to increase R&D spending as oncology trials scale. The company expects 2025 total revenues between $1.9 billion and $2.4 billion, implying further contraction. BioNTech SE is burning through $2.5 billion annually in R&D expenses — 82% of its total revenue — to fund the most aggressive oncology pipeline expansion in the company's 17-year history, while its primary revenue source, the Pfizer-partnered Comirnaty COVID-19 vaccine, collapses from a peak of $20.7 billion in 2021 to a guided $1.9-2.2 billion in 2025. This deliberate, high-stakes reinvestment strategy, funded by $19.0 billion in cash reserves accumulated during the pandemic, represents a make-or-break shift from vaccine manufacturer to diversified oncology biopharmaceutical company. With more than 20 active Phase 2 and Phase 3 clinical trials, a $800 million acquisition of Chinese biotech Biotheus completed in February 2025, and first oncology launches targeted for 2026, BioNTech is racing against its own cash burn rate to validate a pipeline that the market currently values at approximately zero, as evidenced by a price-to-book ratio of 1.0 and a stock price that has declined 80% from its 2021 peak. The BNT327 bispecific antibody targets the PD-1/PD-L1 checkpoint inhibitor market, which exceeded $40 billion in 2024 sales. Merck's Keytruda (pembrolizumab) dominates with $25 billion in annual sales, followed by Bristol Myers Squibb's Opdivo (nivolumab) at approximately $9 billion and Roche's Tecentriq (atezolizumab) at around $4 billion. With $19.0 billion in cash and a $22.7 billion market cap, BioNTech is larger than most pure-play oncology biotechs but smaller than established pharmaceutical companies. For the fiscal year ended December 31, 2024, BioNTech SE reported total revenues of $2998.7 million ($3.0 billion at average 2024 EUR/USD exchange rate of approximately 1.09), representing a 28.0% decline from $4162.7 million in 2023 and an 84.1% decline from the peak of $18868.6 million in 2022. The revenue contraction was entirely attributable to declining COVID-19 vaccine sales, with Comirnaty-related revenues falling from $4116.1 million in 2023 to $2651.0 million in 2024 — a 35.6% decrease. Other revenues increased to $347.7 million (12% of total) from $46.7 million in 2023, primarily from the German Federal Ministry of Health pandemic preparedness contract. The company reported a net loss of $725.2 million for 2024, swinging from net profit of $1014.0 million in 2023. On a per-share basis, this translated to diluted loss per share of $3 ($3.00), compared to diluted earnings per share of $4.2 in 2023. The operating loss was $1765.7 million on a BioNTech SE standalone basis, and the consolidated operating result was similarly negative. Gross profit on a consolidated basis was $2408.7 million ($2998.7 million revenues minus $590.0 million cost of sales), yielding a gross margin of 80.3%. Research and development expenses surged 26.4% to $2457.1 million, consuming 81.9% of total revenues. The R&D split shows $257.2 million for COVID-19 programs (down 25% YoY) and $2199.8 million for non-COVID programs (up 37.3% YoY), with oncology consuming the vast majority. Sales, general and administrative expenses increased 7.4% to $652.9 million, driven by commercial IT platform investments and headcount growth. Other operating result was negative $731.3 million, compared to negative $204.9 million in 2023, primarily due to settlement of contractual disputes and litigation expenses. The finance result was positive $746.3 million, up from $367.1 million in 2023, driven by interest income on the substantial cash reserves. Income from profit transfer totaled $337.4 million, and other interest and similar income contributed $699.1 million. Despite the operating loss, the strong finance result partially offset the deficit, resulting in the pre-tax loss of $1237.4 million. Income taxes provided a $7.3 million benefit, leading to the net loss of $1230.1 million on a standalone basis and $725.2 million on a consolidated basis. Cash and cash equivalents plus security investments totaled $19.0 billion as of December 31, 2024, down modestly from the prior year as cash burn was partially offset by investment returns. Total current assets were $22.1 billion, against total current liabilities of $2.5 billion, yielding a current ratio of 8.8 — exceptional liquidity that provides substantial operational runway. Total equity stood at $23.9 billion, with minimal debt (total debt-to-equity of 1.62%). For 2025, BioNTech has guided total revenues between $1.9 billion and $2.4 billion, implying a further 20-38% decline. The company explicitly states it does not expect positive net income in 2025. At the guided revenue midpoint of $2.1 billion and maintaining R&D at approximately $2.5 billion, the company would burn approximately $1.1-1.2 billion in cash annually, suggesting the $19.0 billion reserves provide 14-17 years of runway at current rates. The financial narrative is therefore one of deliberate, aggressive reinvestment of pandemic-era cash flows into oncology development, with the market capitalization of $22.7 billion reflecting investor skepticism about whether this investment will generate approved products before the cash depletes. The most immediate threat to BioNTech's margin and market position is the structural collapse of COVID-19 vaccine demand, which has already reduced revenues from a peak of $20.7 billion in 2021 to $3.0 billion in 2024 — a decline of 85.5% in just three years. The 2025 revenue guidance of $1.9 billion to $2.4 billion implies a further 20-38% decline from 2024 levels. BNT327, BioNTech's lead bispecific antibody targeting PD-L1 and VEGF-A, enters a market dominated by Merck's Keytruda (pembrolizumab), which generated $25 billion in 2024 sales alone. The 2024 annual report notes that personnel expenses increased by $188.2 million year-over-year to $546.1 million, driven by ESOP exercises, headcount growth, and wage inflation. The company has acknowledged that it does not expect positive net income in 2025, and the path to profitability depends entirely on successful oncology product launches. The cash position of $19.0 billion provides a further competitive advantage: financial flexibility to fund multiple simultaneous late-stage trials, acquire complementary assets (as demonstrated by the Biotheus purchase), and withstand clinical setbacks without dilutive financing. The $800 million Biotheus acquisition was specifically motivated by BNT327's potential and the desire to secure full global rights rather than share economics through the original licensing deal. The company has not provided specific revenue targets for the oncology portfolio, but the addressable market for BNT327 alone exceeds $10 billion if it captures even a modest share of the checkpoint inhibitor market. The cash position of $19.0 billion provides strategic optionality for additional acquisitions if pipeline gaps emerge or competitor assets become available. The company has demonstrated willingness to deploy capital aggressively, as shown by the $800 million Biotheus acquisition and the potential CureVac acquisition (terms not yet finalized as of the 2024 reporting date). Revenues exploded from $525.7 million in 2020 to $20.7 billion in 2021. The stock price, which had traded in the $20-30 range during 2019-2020, surged above $450 in 2021, creating a market capitalization that briefly exceeded $100 billion.